



Amarantus Therapeutics

Amarantus Therapeutics, Inc.
c/o The Parkinson's Institute
675 Almanor Ave.
Sunnyvale, CA 94085
www.amarantustherapeutics.com

You are cordially invited to attend Amarantus Therapeutics, Inc. Luncheon Presentation on Tuesday, March 2nd, 2010 at the Offices of Wilson Sonsini Goodrich & Rosati

What: Research Analyst Luncheon with Amarantus Therapeutics, Inc.


Who is Amarantus: [Amarantus Therapeutics](#) is a pre-clinical stage, privately-held biotechnology company developing first-in-class treatments for diseases associated with apoptosis. Amarantus is currently focusing on the development of its lead drug candidate AMRS001 (MANF-protein) for Parkinson's Disease and Ischemic Heart Disease.

[Video Interview with Martin Cleary, Amarantus CEO](#)

When: Tuesday, March 2nd, 2010, 12:30-1:45 pm
Luncheon registration beginning at 12:00 pm

Where: [Wilson Sonsini Goodrich & Rosati](#)
1301 Avenue of the Americas
40th Floor
Conference Room D
New York, NY 10019-6033

RSVP: Susan Kim and Chelli Miller
rsvp@amarantustherapeutics.com
RSVP required for elevator access



Parkash et al (2009) PEDS

Investment Highlights

1. Amarantus is a pre-clinical stage, privately-held biotechnology company developing "first-in-class" treatments for diseases associated with apoptosis.
2. AMRS001 is designed to help reverse the damage from "programmed cell death." It is believed AMRS001 could be the next EPO (Erythropoietin).
3. Parkinson's Disease is the first therapeutic indication for AMRS001. AMRS001 has the potential to arrest the progression and reverse the symptoms of Parkinson's Disease.
4. Amarantus' proprietary PhenoGuard Cell Line technology platform will yield additional multi-purposed, high-value Therapeutic Proteins.
5. Amarantus is adopting a tech-style partnering/out-licensing program to broadly advance the development of our therapeutic proteins and PhenoGuard platform for a wide range of disorders. Therapies are being positioned as improvements on current therapies rather than replacements.